International Stem Cell Corporation (OTCQB: ISCO) is a
biotechnology company that focuses on early-stage cell therapy. ISCO uses stem
cells to treat a variety of diseases, including those of the eyes, the nervous
system, and the liver, among others. The scientists at ISCO treat severe
diseases with state-of-the-art technology. The aim of the company is to create
therapeutic products from its own intellectual property. With this in mind,
ISCO also owns two subsidiary companies. Lifeline Skin Care Inc. is a business
that develops and manufactures skin care products, while Lifeline Cell
Technology, LLC is a research products business that develops and manufactures
human cell culture products.
Most recently, International Stem Cell Corp. has started
developing human parthenogenetic stem cell derived neural stem cells. Over the
past few years, the main problem with using stem cells in regenerative medicine
has been a case of ethics. In an article entitled ‘Embryonic stem cell
research: an ethical dilemma’, published on the Euro Stem Cell website, it
explains the dilemma that we, as humans, have to face when making a choice
between two moral principles: the duty we have to prevent or diminish pain and
suffering, and the duty we have to respect the value of human life, even at its
earliest stages. In the article, the discussion goes into detail about the
moral status of a human embryo. The question is asked: Does the embryo have the
status of a person? The answer is still to be decided.
However, with the help of International Stem Cell Corp., the
discussion can be put to one side for the time being. ISCO has developed a new
type of stem cell using unfertilized eggs. This means that the eggs in question
would never have the potential to become embryos, and, therefore, no embryo is
destroyed. During a recent interview between The Nikkei Asian Review and
Russell Kern, Chief Scientific Officer at ISCO, Kern said: “Being able to
produce parthenogenetic stem cells in large quantities and in a way that
greatly simplifies the chances of immune matching gives us a clear advantage
over other stem cell technologies, like embryonic stem cells for obvious
reasons. One of ISCO’s stem cell lines matches approximately 70 million people
and makes it incredibly simple to immune match its stem cells.”
ISCO is starting a phase I clinical trial in Australia using
these new stem cells. The stem cells not only take away any moral issues
associated to the cause but may also reduce the risk of immune rejections. The
phase I clinical trials are based on preclinical studies in rodents and
nonhuman primates. The ISCO stem cells showed a significant rise in brain
dopamine levels. Not only this, the studies also showed amazing improvement in
Parkinson’s disease symptoms. With phase I of clinical trials, ISCO aims to
find a treatment for Parkinson’s disease.
For more information, visit www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment